Immuneering (IMRX) Net Cash Flow (2020 - 2026)

Immuneering's Net Cash Flow history runs 7 years deep, the most recent figure standing at -$81.3 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 29045.69% year-over-year to -$81.3 million; the TTM figure through Mar 2026 stood at $11.5 million (up 137.66% YoY), while the FY2025 annual figure was $92.5 million, up 497.66% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$81.3 million, up from -$98.9 million in the prior quarter.
• The five-year high for Net Cash Flow was $201.2 million in Q3 2025, with the low at -$98.9 million in Q4 2025.
• The 5-year median for Net Cash Flow is -$6.6 million (2024), against an average of -$1.6 million.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow soared 1485.45% in 2025, then sank 29045.69% in 2026.
• Immuneering's Net Cash Flow stood at -$3.8 million in 2022, then plunged by 128.37% to -$8.6 million in 2023, then fell by 4.94% to -$9.1 million in 2024, then sank by 991.71% to -$98.9 million in 2025, then advanced by 17.79% to -$81.3 million in 2026.
• Business Quant data shows IMRX's Net Cash Flow at -$81.3 million in Q1 2026, -$98.9 million in Q4 2025, and $201.2 million in Q3 2025.